| 摘要 |
<p>This invention provides an agent capable of destruction of CD52+ cells, including CD52+ dendritic cells, without affecting CD52 negative dendritic cells. CD52 negative dendritic cells include but are not limited to Langerhans cells (LCs) or dermal-interstitial dendritic cells (DDC-IDCs). This invention also provides an agent capable of selective elimination of CD52+ dendritic cells. This invention further provides an agent capable of protection of CD52 negative dendritic cells as well as a composition comprising the above described agent, a pharmaceutical composition comprising an effective amount of the above agent, and a pharmaceutically acceptable carrier. Finally, this invention provides various uses of the above agent and the above compositions.</p> |
